Agilent Technologies, Inc.
NYSE:AMedical - Diagnostics & Research
+$3.04 today
- Market cap
- $50.00B
- Beta
- 1.26
- P/E (TTM)
- 25.5
- EPS (TTM)
- $5.00
- Dividend yield
- 0.59%
Volume 2.48M
Average 2.24M
A EBITDA Margin
EBITDA as a percentage of revenue.
Agilent Technologies, Inc.NYSE: A
EBITDA Margin · Q3 FY2026 · quarter ended Jul 2026
EBITDA Margin widens to 28.7%
EBITDA Margin was 28.7% in Q3 FY2026, up 1.9 pp from a year earlier. On a trailing-twelve-month basis it was 27.6%, up 1.1 pp year over year. Over 3 fiscal years it narrowed by 1.4 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 15 analysts of 32.5% for the fiscal year ending Oct 2026, up from 26.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJul 2026
- 28.7%+1.5 pp QoQ
- Last fiscal yearOct 2025
- 26.4%-2.4 pp YoY
- LTMJul 2026
- 27.6%+1.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.9 pp | +3.6 pp | +1.7 pp |
| 1 year | -2.4 pp | +6.1 pp | +8.4 pp |
| 3 years | -1.4 pp | +6.5 pp | +7.9 pp |
| 5 years | +9.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 26.4%
- Year-over-year change
- -2.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 26.4% | -2.4pp |
| FY2024 | 2024-10-31 | 28.8% | +3.9pp |
| FY2023 | 2023-10-31 | 24.9% | -2.9pp |
| FY2022 | 2022-10-31 | 27.8% | -0.1pp |
| FY2021 | 2021-10-31 | 27.9% | — |
EBITDA Margin vs competitors
How A compares with its peers on the latest reported figures
- A's LTM Jul 2026 EBITDA Margin of 27.6% is the 4th highest of the 9 companies compared; the peer median is 25.0%.
- Its year-over-year change of +1.1 pp is the highest of 9, against a peer median of -2.6 pp.
- Over three fiscal years its change of -1.4 pp compares with a peer median of -2.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 33.5% | -1.6 pp | -2.1 pp | |
| LTM Jun 2026 | 31.6% | +0.0 pp | -0.7 pp | |
| LTM Sep 2026 | 27.7% | -0.6 pp | -7.3 pp | |
| LTM Jul 2026 | 27.6% | +1.1 pp | -1.4 pp | |
| LTM Jul 2026 | 26.3% | -3.0 pp | -8.9 pp | |
| LTM Sep 2026 | 23.7% | -2.2 pp | -0.9 pp | |
| LTM Jul 2026 | 20.5% | -14.2 pp | -2.3 pp | |
| LTM Jun 2026 | 19.9% | -6.2 pp | +208.5 pp | |
| LTM Jun 2026 | 7.1% | -4.6 pp | -11.7 pp | |
| Peer median (excluding A) | 25.0% | -2.6 pp | -2.2 pp | |
Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 6.32B | 6.85B | 6.83B | 6.51B | 6.95B |
| Cost of Revenue | 2.91B | 3.13B | 3.37B | 2.98B | 3.31B |
| Gross Profit | 3.41B | 3.72B | 3.47B | 3.54B | 3.64B |
| Gross Margin | 53.9% | 54.4% | 50.7% | 54.3% | 52.4% |
| Research & Development | 441M | 467M | 481M | 479M | 455M |
| Selling, General & Admin | 1.62B | 1.64B | 1.63B | 1.52B | 1.71B |
| Operating Expenses | 2.06B | 2.1B | 2.12B | 2.05B | 2.16B |
| Depreciation & Amortization | 321M | 317M | 271M | 257M | 288M |
| EBITDA | 1.76B | 1.91B | 1.7B | 1.87B | 1.84B |
| EBITDA Margin | 27.9% | 27.8% | 24.9% | 28.8% | 26.4% |
| Operating Income | 1.35B | 1.62B | 1.35B | 1.49B | 1.48B |
| Operating Margin | 21.3% | 23.6% | 19.8% | 22.9% | 21.3% |
| Interest Income | 2M | 9M | 51M | 80M | 62M |
| Interest Expense | 81M | 84M | 95M | 96M | 112M |
| Other Income / Expenses | 13M | (114M) | (11M) | 33M | (44M) |
| Income Before Tax | 1.36B | 1.5B | 1.34B | 1.52B | 1.44B |
| Pre-Tax Margin | 21.5% | 22.0% | 19.6% | 23.4% | 20.7% |
| Income Tax Expense | 150M | 250M | 99M | 232M | 132M |
| Net Income | 1.21B | 1.25B | 1.24B | 1.29B | 1.3B |
| Net Margin | 19.1% | 18.3% | 18.1% | 19.8% | 18.8% |
| EPS (Basic) | 3.98 | 4.19 | 4.22 | 4.44 | 4.59 |
| EPS (Diluted) | 3.94 | 4.18 | 4.19 | 4.43 | 4.57 |
| Weighted Avg Shares | 304M | 299M | 294M | 290M | 283M |
| Weighted Avg Shares (Diluted) | 307M | 300M | 296M | 291M | 284M |
Agilent Technologies, Inc.
NYSE:A
Intrinsic Alpha fair value
Locked
Current Price
$177.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.